Table 2 Adherence to controller and nebulized SAMAs and SABAs, by study group.

From: Overuse of reliever inhalers and associated healthcare utilization of asthma patients

  Refilled ≥ 3 prescriptions of canisters of relievers annually Refilled < 3 prescriptions of canisters of relievers annually P value
Annual average PDC of MARTa 0.27 ± 0.36 (0.01, 0.54) 0.15 ± 0.26 (0.03, 0.17) 0.052
Max annual average PDC of controllers (excluding MART)b 0.38 ± 0.34 (0.34, 0.58) 0.24 ± 0.26 (0.13, 0.36)  < 0.001
Annual average number of packages of nebulized SAMAs and SABAsc 1.80 ± 8.34 (0.17, 0.75) 0.67 ± 2.19 (0.00, 0.50) 0.068
  1. Values are mean ± SD (median, IQR).
  2. aMART, maintenance and reliever therapy.
  3. bThese controllers include inhaled corticosteroids (ICS) inhalers, leukotriene receptor antagonists (LTRA), ICS + long-acting β2 -agonist (LABA) combinations inhalers, and Theophylline, and exclude controller therapy administered by nebulizers.
  4. cNebulized short acting beta2 agonist (SABA) and short-acting muscarinic antagonists (SAMA).